Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Sosei Looks To Add Value Through Pipeline Progress

Japan-based Sosei is building up its portfolio of in-house assets on top of technology and molecule licensing deals as it looks to create value over the next few years following the acquisition of Heptares, say executives.

Japan Research & Development

Opdivo, Keytruda Hit Again As Japan Revises Prices

Immuno-oncology drugs Opdivo and Keytruda will have their prices cut in the next regular Japanese price revision in April, while some other novel and big-selling products will also feel the heat under a revised framework.
Japan Reimbursement

Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline

Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.

Deals M & A

More US Positions Go As Daiichi Sankyo Refocuses

Attempts to maximize the current commercial portfolio and prepare for upcoming pipeline launches spell more job losses at the US arm of major Japanese pharma Daiichi Sankyo.

United States Commercial

Pfizer Japan Cautious Over New Policies As Sales Slip

Despite a fall in local revenues, Pfizer remains bullish on its newer products and pipeline in Japan but is cautious about this year's planned price reforms in the country.

Japan Commercial

Interview: Setting The Course For Takeda’s R&D Future (Part 2)

Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company’s chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 12 months.

Commercial Strategy
See All